Clare Sun, MD
Patients with newly diagnosed or relapsed/refractory chronic lymphocytic leukemia (CLL) achieved objective response rates as high as 100% with either of 2 doses of the BTK inhibitor acalabrutinib (Calquence), results of an open-label phase II trial showed.
Serious AEs occurred in 18 (38%) of 48 patients, including grade ≥3 in 13 (27%) patients. AEs leading to discontinuation consisted of one case each of hepatocellular injury, lung adenocarcinoma, and myelodysplastic syndrome.
Sun CC, Nierman P, Ahn IE, et al. Acalabrutinib in patients with relapsed/refractory (R/R) and high-risk, treatment-naive (TN) chronic lymphocytic leukemia (CLL). Presented at: ASH Annual Meeting and Exposition; December 4-8, 2018; San Diego, California. Abstract 4424.
... to read the full story